Clinical trial · Interventional
Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas
Exosomes and Resistance to Immunotherapy in Aggressive Non-Hodgkin B-cell Lymphomas (B-NHL)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Diffuse large B-cell lymphomas (DLBCL) are highly aggressive and heterogeneous B-cell lymphoma that would imminently be fatal without treatment. Monoclonal anti-CD20 antibody, rituximab, in combination of CHOP chemotherapy (R-CHOP) is widely used with favourable results. Although more than half of patients achieve long-term remission, many are not cured with this immunotherapy. Suboptimal response and/or resistance to rituximab have remained a challenge in the therapy of DLBCL but also of all B-NHL. Exosomes are microvesicles released from tumor B cells that are found in plasma of patients with B-NHL. Exosomes carry therapeutic targets (as CD20, PDL-1) and could act as "decoy-receptors" for immunotherapy. Our objective is to precise, in aggressive B-NHL, the role of exosomes in immunotherapy escape.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL) | Lymphoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood sample | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- patients with DLBCL
- interventionNames
- Other: blood sample
- type
- ACTIVE_COMPARATOR
- label
- Healthy volunteers
- interventionNames
- Other: blood sample
Primary outcomes (1)
- measure
- Quantification of CD20 and PDL-1 in exosomes purified from cell cultures of DLBCL human cell lines and from Healthy volunteers
- timeFrame
- Month 36
- description
- From D0 until the end of the inclusion period (36 months)
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria : * patients over 18 years old with DLBCL at diagnostic or relapsed patients after R-CHOP therapy. * Healthy volunteers over 18 years old Exclusion Criteria: * other B cell diseases
References
Publications (1)
- RESULTAkil H, Bentayeb H, Aitamer M, Vignoles C, Abraham J, Gachard N, Olivrie A, Guyot A, Gobbo J, Feuillard J, Shirvani H, Troutaud D. Analysis of CD20 and PD-L1 levels on small extracellular vesicles (sEV) produced by DLBCL cells and EBV-transformed B cells, and potential role in T cell inhibition. Exp Hematol Oncol. 2024 May 17;13(1):53. doi: 10.1186/s40164-024-00518-2. PMID 38760788